TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01712659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
Study: NCT00526838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL228
Description: 1-hour IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL228
Description: 1-hour IV infusion
Study: NCT04258202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Description: The two methods for performing an alveolar recruitment maneuver. Alveolar recruitment maneuvers consisted of a stepwise increase in tidal volume to a plateau pressure of 30 cm H2O versus a stepwise increase in PEEP H2O to a plateau pressure of 30 cm H2O.
Study: NCT02388451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feuerstein Program
Description: The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
Study: NCT01140906

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets, daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets, daily, orally

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: encapsulated capsules, daily, orally
Study: NCT01973751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled powder of inhaled corticosteroid, 2 puffs (200mcg) twice a day for 8 weeks
Study: NCT05084391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy (SABR)
Description: is safe for treating heart arrhythmias (irregular heartbeat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy (SABR)
Description: is safe for treating heart arrhythmias (irregular heartbeat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Treatment
Description: Standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Treatment
Description: Standard of care
Study: NCT03632824

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: One gram( 2 ampules ) of tranexamic acid was received by the participant intravenously twice daily for 48 hours followed by 500 mg tranexamic acid tablet three times daily for 5 days .~follow up of the patient was done by recurrence of the bleeding latter on during pregnancy . the course of treatment was repeated again .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: One gram( 2 ampules ) of tranexamic acid was received by the participant intravenously twice daily for 48 hours followed by 500 mg tranexamic acid tablet three times daily for 5 days .~follow up of the patient was done by recurrence of the bleeding latter on during pregnancy . the course of treatment was repeated again .
Study: NCT03705325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirobank Smart spirometer
Description: The spirometer is a compact, portable, home-based spirometer that pairs with a smartphone app. Exhaled air flow causes the turbine to rotate, generating a voltage analogous to the rate of air flow across the turbine. The spirometer measures Forced expiratory volume in 1 second (FEV1), or the volume of air that is exhaled in the first second. The device prompts the user to perform a minimum of three expiratory maneuvers in and records the best of the three maneuvers. The information generated is then transmitted to the VitalFlo App (password protected) on the user's iPhone. The user is alerted, by the App, if their expiratory effort is inadequate (such as early termination of exhalation) and is provided coaching for proper technique.
Study: NCT04202835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Post Transplant Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte globulin (rabbit)
Description: Anti-Thymocyte Globulin (rabbit, Thymoglobulin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte globulin (rabbit)
Description: Anti-Thymocyte Globulin (rabbit, Thymoglobulin)
Study: NCT03294915

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: Addition of 42g per day of green banana flour (10g / day resistant starch) to the usual diet of study participants

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Addition of 42g per day of mixture of guar gum, maltodextrin and cellulose to the usual diet of study participants
Study: NCT03174639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverted and free ILM insertion
Description: ILM was peeled and the ILM flap was inverted and inserted into the macular hole, followed by insertion of free ILM flap.
Study: NCT03592628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Aid
Description: The visual aid was a one-sheet diagram with illustrations of important features of post-cesarean wound care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Instructions
Description: Standard discharge instructions WITHOUT supplement of visual aid.
Study: NCT05152121

Intervention type: OTHER
Group type: OTHER
Intervention: Carb and fat counting
Description: In the 7 days leading up to the study, participants were contacted to review blood glucose levels with CGMS, food and activity diary. basal rates and insulin carbohydrate ratio and sensitivity factor were changed according to the CGMS values and normoglycemia was achieved.In the study day same meals were served which included high fat, high energy density test meal containing 80 gram carbohydrate (34%), 70 gram fat (66%) and 35 g protein (14%).The participants had to have no glucose fluctuations 2 hours before study entry based on CGMS, no correction boluses for at least 4 hours before the test meal consumption and fasting glycemia in the range of 70-180 mg/dL on both study days.The participants received the test meal calculating insulin dose by CC on the first study day and calculating insulin dose by and fat/protein counting in the second study day. The test meal consumption was completed in 20 minutes under supervision by a caregiver and a dietician of the research team
Study: NCT00961064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety
Study: NCT02397525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202
Study: NCT03349463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: All study participants will receive 10 mCi of 18F-Fluciclovine (Axumin) one time administered through injection through the catheter into participant's arm immediately before PET/CT scan.
Study: NCT00947544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaPBA
Description: NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
Study: NCT01860209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)
Study: NCT05300386

Intervention type: DRUG
Intervention: Escitalopram
Description: We use Escitalopram 5\~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder

Intervention type: DRUG
Intervention: Escitalopram
Description: We use Escitalopram 5\~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder
Study: NCT03329885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986251
Description: Escalating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986251
Description: Escalating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986251
Description: Escalating oral dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Escalating oral dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Escalating oral dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Escalating oral dose
Study: NCT04698811

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VIRTUAL ENEAGRAM
Description: Presentation of the Virtual Enneagram and its content and realization of the first battery of tests (World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: IDATE E and T.) .~Guidance and training on personality and the Enneagram, its classification system, personality subtypes and dynamics of stress and growth allowing self-recognition.~Second test battery ((World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: (IDATE E and T.) and Enneagram Questionnaire.
Study: NCT02106507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apalutamide
Description: apalutamide, 240 mg/day, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
Study: NCT03968809

Intervention type: DIAGNOSTIC_TEST
Intervention: CardioFlux Magnetocardiography
Description: All patients enrolled and receiving standard screening tests for CAD will undergo a 2 minute scan with MCG. It will be determined if MCG scanning can provide equal or superior accuracy to predict MACE than standard testing.
Study: NCT03097601

Intervention type: DIAGNOSTIC_TEST
Intervention: ELR+CXCL cytokines levels are of sunitinib response
Description: Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
Study: NCT03394937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECI-006
Description: ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECI-006
Description: ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECI-006
Description: ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECI-006
Description: ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules
Study: NCT02526238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS and trunk rotation
Description: TMS and trunk rotation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS and trunk rotation
Description: Sham TMS and trunk rotation
Study: NCT04828499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Cracking Technique
Description: Performing the cataract surgery with our phaco chop-progressive cracking technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Chop Technique
Description: Performing the cataract surgery with Conventional Chop Technique.
Study: NCT00596492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DYME
Description: 2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DYME
Description: 2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
Study: NCT01060501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid, interferon-alpha
Description: 5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid, interferon-alpha
Description: 5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid, interferon-alpha
Description: 5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
Study: NCT02014623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grass pollen sublingual immunotherapy tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Control
Study: NCT04400318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: solution for injection subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection subcutaneous
Study: NCT01902667

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Study: NCT04084015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axillary Impella®
Description: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy
Study: NCT03051711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Capsules which contain GBT440 drug substance in Swedish Orange

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Capsules which contain GBT440 drug substance in Swedish Orange
Study: NCT04319705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: capsule containing placebo, 3 times per week, 12-week treatment period, administered orally
Study: NCT00312442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with WST09 Vascular Photodynamic therapy
Study: NCT03332342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye wash
Description: Research subjects will perform a wash of their ocular surface with phosphate buffered saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye wash
Description: Research subjects will perform a wash of their ocular surface with phosphate buffered saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye wash
Description: Research subjects will perform a wash of their ocular surface with phosphate buffered saline
Study: NCT03371550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Induction chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concomitant radiotherapy
Description: Pulmonary and mediastinal radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction chemotherapy
Study: NCT02805023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGC101 (autologous EnEPC preparation)
Description: Intramuscular injections - single treatment session

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control medium
Description: Intramuscular injections - single treatment session
Study: NCT03245606

Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: Measurement of liver fibrosis

Intervention type: DEVICE
Intervention: Abdominal MRI
Description: Measurement of liver fibrosis

Intervention type: DEVICE
Intervention: Transient elastography
Description: Measurement of liver fibrosis
Study: NCT03257579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 90 Day Supply
Description: Policy Change implementing a 90 day standardized discharge prescription form with 3 repeats for all cardiac medications available on all wards where MI patients are managed at Hamilton Health Sciences sites
Study: NCT03257579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education Alone provided at St. Joseph's Hospital and Niagara Health System
Study: NCT04111302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV-PCA
Description: IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV-dezocine
Description: IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV-PCA+AA
Description: IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h. And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV-dezocine+AA
Description: IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
Study: NCT01366391

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Metformin 500 mg tablet (1000 or 1500 mg/day)
Study: NCT00806065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Study: NCT01859039

Intervention type: BIOLOGICAL
Intervention: Administration of Live attenuated influenza vaccine
Study: NCT01115270

Intervention type: OTHER
Intervention: Non-invasive measures
Description: assessment of cerebrovascular fluid movement

Intervention type: OTHER
Intervention: Non-invasive measures
Description: assessment of cerebrovascular fluid movement
Study: NCT02328508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
Study: NCT02426684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IdeS® (Imlifidase)
Description: 0.24mg/kg IdeS
Study: NCT03095131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart Spectrum Blood Pressure Monitor
Description: The Heart Spectrum Blood Pressure Monitor provides a convenient and effective filtering application compared with traditional methods that require a visit to a physician for a 12-lead ECG.
Study: NCT02534506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT00526500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tilt Table With Integrated Stepping System
Description: Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tilt Table With Integrated Stepping System
Description: Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tilt Table With Integrated Stepping System
Description: Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tilt Table With Integrated Stepping System
Description: Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.